| Literature DB >> 33920845 |
Daniele Nucci1, Cristina Fatigoni2, Tania Salvatori2, Mariateresa Nardi1, Stefano Realdon3, Vincenza Gianfredi4,5.
Abstract
PubMed/Medline, Excerpta Medica dataBASE (EMBASE) and Scopus were searched in January 2021 in order to retrieve evidence assessing the association between dietary fibre intake and the risk of colorectal adenoma in adults. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for the reporting of results. Only primary observational studies were included. Publication bias was estimated through the Egger's test and the visual inspection of the funnel plot. Heterogeneity between studies was calculated with I2 statistics. The search strategy identified 683 papers, 21 of which were included in our meta-analysis. Having evaluated a total of 157,725 subjects, the results suggest a protective effect of dietary fibre intake against colorectal adenoma. Effect Size (ES) was [0.71 (95% CI = 0.68-0.75), p = 0.000)]. Moderate statistical heterogeneity (Chi2 = 61.68, df = 23, I2 = 62.71%, p = 0.000) was found. Findings show a statistically significant (p = 0.000) and robust association between a higher intake of dietary fibre and a lower risk of colorectal adenoma, considering both the prevalent and incident risk. Moreover, the meta-regression analysis showed a borderline significant negative linear correlation between the amount of dietary fibre intake and colorectal adenoma. Lastly, we performed a subgroup analysis by sex, showing a higher protective effect for men.Entities:
Keywords: adenoma; colorectal; diet; fibre; systematic review
Year: 2021 PMID: 33920845 PMCID: PMC8071151 DOI: 10.3390/ijerph18084168
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow diagram of the studies’ selection process.
Qualitative characteristics of included studies, reported in alphabetical order.
| Author, Year [Ref] | Country | Study Period | Study Design | Population Characteristics | Tool | Diagnostic Assessment | Funds | Conflicts of Interest |
|---|---|---|---|---|---|---|---|---|
| Breuer-Katschinski, 2001 [ | Germany | 2 years | Case-controls | Patients from five major hospitals in Essen; controls were selected from among hospital patients and stratified by sex | Personal interview not validated | Endoscopy and histology | yes | n.a. |
| Breuer-Katschinski, 2001 (a) [ | Germany | 2 years | Case-controls | Patients from five major hospitals in Essen; controls were selected from among the general population and stratified by sex | Personal interview not validated | Endoscopy and histology | yes | n.a. |
| Byrd, 2020 [ | USA | 1991–19941994–19972002 | Case-controls | MAP I and MAP Il | Validated self-administered 61-FFQs and 98-FFQ | Colonoscopy and histology | yes | yes |
| Fu, 2014 [ | USA | 7 years | Case-controls | TCPS | Validated self-administered 108-FFQ | Colonoscopy and histology | yes | no |
| Fuchs, 1999 [ | USA | 16 years | Cohort | Without history of cancer, IBD, or familial polyposis | Validated self-administered 136-FFQ | Medical records | n.a. | n.a. |
| Giovannucci, 1992 [ | USA | 2 years | Cohort | HPF | Validated self-administered 131-FFQ | Endoscopy and histology | n.a. | n.a. |
| Haile, 1997 [ | USA | 2 years | Case-controls | Screening sigmoidoscopy subjects from 2 Southern California Kaiser Permanente Medical Centers | Validated 126-item semi-quantitative FFQ | Sigmoidoscopy and histology | yes | n.a. |
| Haslam, 2017 [ | USA | 7 years | Cohort | PLCO | Validated questionnaire 137-FFQ | Sigmoidoscopy and histology | no | yes |
| Hoff, 1986 [ | Norway | Case-controls | Endoscopic population screening study | Food diary for 5 consecutive days | Rectosigmoidoscopy | n.a. | n.a. | |
| Kunzmann, 2015 [ | USA | 13 years | Cohort | PLCO outcome stratified by adenoma site (incident) | Validated self-administered 137-FFQ | Sigmoidoscopy and histology | n.a. | no |
| Kunzmann, 2015 (a) [ | USA | 13 years | Cohort | PLCO outcome stratified by adenoma site (recurrent) | Validated self-administered 137-FFQ | Sigmoidoscopy and histology | n.a. | no |
| Little, 1993 [ | UK | 7 years | Case-controls | Subjects recruited in a colorectal cancer screening trial in Nottingham | Interview conducted at the subject’s home by specially trained interviewers | Colonoscopy and histology | yes | n.a. |
| Lubin, 1997 [ | Israel | 3 years | Paired Case-controls | Subjects identified in the SPGD at the Tel Aviv Medical Center | 180-item questionnaire (interview) | Endoscopy and histology | n.a. | n.a. |
| Martìnez, 1996 [ | USA | 2 years | Case-controls | Population without history of colorectal polyps and familial polyposis | 138-FFQ (interview) validation n.a. | Sigmoidoscopy or colonoscopy and histology | n.a. | n.a. |
| Mathew, 2004 [ | USA | 2 years | Case-controls | Subjects with new or recurrent adenomas in a study conducted at the NNMC | Validated self-administered 100-item | Sigmoidoscopy or colonoscopy and histology | n.a. | n.a. |
| Mujtaba,2018 [ | USA | 1991–19941994–19972002 | Case-controls | CPRU | Validated self-administered 61-FFQs | Colonoscopy and histology | n.a. | no |
| Nimptsch, 2014 [ | USA | 9 years | Cohort | NHS II | Validated self-administered 131-FFQ | Medical record | yes | n.a. |
| Peters, 2003 [ | USA | 7 years | Case-controls | PLCO | Self-administered 137-FFQ (adaptation from previous validated FFQ) | Endoscopy and histology | n.a. | n.a. |
| Platz, 1997 [ | USA | 8years | Cohort | HPF | Validated self-administered 131-FFQ) | Sigmoidoscopy or colonoscopy and histology | yes | n.a. |
| Sandler, 1993 [ | USA | 2 years | Case-controls | Subjects who underwent colonoscopy at the University of North Carolina Hospitals | Validated quantitative food frequency questionnaire (interview) | Sigmoidoscopy or colonoscopy and histology | n.a. | n.a. |
| Shaw, 2017 [ | USA | 7 years | Cross-sectional | FMCCSC | DHQ I or II | Colonoscopy and histology | yes | no |
| Tantamango, 2011 [ | USA | 26 years | Cohort | AHS-1 and AHS-2 | Self-administered 55-FFQ validation n.a. | Self-reported | yes | no |
| Witte, 1996 [ | USA | 2 years | Paired Case-controls | Subjects free of invasive cancer, IBD and familial polyposis | Validated self-administered 126-FFQ | Sigmoidoscopy and histology | n.a. | n.a. |
n.a.: not available; no: declared, but conflicts of interest absent; yes: declared and present. AHS: Adventist Health Study; CPRU: Cancer Prevention Research Unit Study; DHQ: Diet History Questionnaire; FFQ: food frequency questionnaire; FMCCSC: Forzani &MacPhail Colon Cancer Screening Centre; IBD: Inflammatory bowel disease; HPF: Health Professionals Follow-up Study MAP: Markers of Adenomatous Polyps; NHS: Nurses’ Health Study; NNMC: National Navy Medical Center; NSAID: Nonsteroidal anti-inflammatory drug; PA: Physical Activity; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SAF: Saturated fatty acids; SPGD: Screening Program of the Gastroenterology Department; TCP: Tennessee Colorectal Polyp Study; TEn: Total Energy intake; UK: United Kingdom; USA: United States of America.
Quantitative characteristics of included studies, reported in alphabetical order.
| Author, Year [Ref] (Number of Stratified Analysis) | Total Sample ^ | Sex | Age (In Years) | Dietary Fibre | Outcome | n. Subjects at the Highest Fibre Intake | Highest Dietary Fibre Intake | Effect Size (95% CI) | Adjustment |
|---|---|---|---|---|---|---|---|---|---|
| Breuer-Katschinski, 2001 [ | Ca: 182 | Ca: M = 94 | Ca: 63.8 ± 9.9 | Ca: 23.01 ± 7.68 g/d | colorectal adenoma | n.a. | n.a. | RR 0.47 | TEn, BMI, and social class |
| Breuer-Katschinski, 2001 [ | Ca: 94 | Ca: M = 94 | Ca: 63.8 ± 9.9 | n.a. | RR 0.16 | ||||
| Breuer-Katschinski, 2001 [ | Ca: 88 | Ca: F = 88 | Ca: 63.8 ± 9.9 | n.a. | RR 0.66 | ||||
| Breuer-Katschinski, 2001 (a) [ | Ca: 182 | Ca: M = 94 | Ca: 63.8 ± 9.9 | Ca: 23.01 ± 7.68 g/d | colorectal adenoma | n.a. | n.a. | RR 0.87 | TEn, BMI, and social class |
| Breuer-Katschinski, 2001 (a) [ | Ca:94 | Ca: M = 94 | Ca: 63.8 ± 9.9 | n.a. | RR 0.38 | ||||
| Breuer-Katschinski, 2001 (a) [ | Ca: 88 | Ca: F = 88 | Ca: 63.8 ± 9.9 | n.a. | RR 0.86 | ||||
| Byrd, 2020 [ | Ca: 765 | Ca: M = 462 | Ca: 58.2 ± 9.2 | Ca: 10.9 ± 3.7 g/1000 kcal/d | colorectal adenoma | n.a. | n.a. | OR 0.82 | none |
| Fu, 2014 [ | Ca: 1315 | Ca: M = 913 | Ca: 59.2 | Ca: 17.0 ± 1.0 g/d | colorectal adenoma | Ca: 278 | 24.8 g/d | OR 0.85 | Age, sex, sites, education, smoking, PA, food supplement, dietary calcium and folate intake, and TEn |
| Fuchs, 1999 [ | 27,530 | only F | 49 | n.a. | colorectal adenoma | Ca: 212 | 24.9 ± 5.5 g/d | RR: 0.91 | Age, smoking, BMI, PA, aspirin use, family history of CRC, history of colorectal adenoma, red meat intake, alcohol, TEn, folate, methionine, calcium, vitamin D intake |
| Giovannucci, 1992 [ | 7284 | only M | 40–75 (range) | n.a. | colorectal adenoma | n.a. | ≥28.3 g/d | RR: 0.36 | Age, TEn, and family history of CRC |
| Haile, 1997 [ | Ca: 488 | Ca: M = 325 | Ca: 61.9 ± 6.7 | Ca: 19.1 g/d | colorectal adenoma | n.a. | 27.6 g/d | OR: 0.52 | BMI, TEn, PA, smoking and ethnicity |
| Haslam, 2017 [ | 24,251 | Ca: M = 1418 | 55–74 (range) | n.a. | colorectal adenoma | Ca: 796 | 26.8 ± 10.8 g/d | OR 0.57 | none |
| Hoff, 1986 [ | Ca: 23 | Ca: M: 16 | 50–59 (range) | Ca: 18.3 ± 1.2 M | rectal adenoma | n.a. | n.a. | OR: 0.36 | none |
| Hoff, 1986 [ | Ca: F: 7 | Ca: 18.9 ± 2.0 F | OR: 0.34 | ||||||
| Kunzmann, 2015 [ | 19,258 | Ca: M = 665 | Ca: 66.6 ± 5.0 | Ca: 11.2 ± 3.5 g/1000 kcal | colorectal adenoma | Ca: 270 | ≥12.8 g/1000 kcal | OR: 0.76 | Age, sex, study center, ethnicity, TEn, smoking status, alcohol intake, total folate intake from diet |
| Kunzmann, 2015 [ | Ca: 770 | colon adenoma | Ca: 206 | OR: 0.75 | |||||
| Kunzmann, 2015 [ | Ca: 262 | rectal adenoma | Ca: 69 | OR 0.68 | |||||
| Kunzmann, 2015 (a) [ | Ca: 738 | Ca: M = 535 | Ca: 66.9 ± 5.3 | Ca: 11.1 ± 3.4 g/1000 kcal | recurrent colorectal adenoma | Ca: 203 | ≥12.8 g/1000 kcal | OR: 1.08 | Age, sex, study center, ethnicity, TEn, smoking status, alcohol intake, total folate intake from diet |
| Kunzmann, 2015 (a) [ | Ca: 257 | recurrent colon adenoma | Ca: 70 | OR: 0.99 | |||||
| Kunzmann, 2015 (a) [ | Ca: 78 | recurrent rectal adenoma | Ca: 26 | OR: 0.88 | |||||
| Little, 1993 [ | Ca: 147 | Ca: M = 65 | Ca: 66.0 ± 7.0 | Ca: 25.5 g/d | colorectal adenoma | Ca: 26 | 38 g/d | RR: 0.81 | Age, sex, social class and total energy intake |
| Lubin, 1997 [ | Ca: 196 | Ca: M = 111 | 21–75 (range) | n.a. | colorectal adenoma | n.a. | >34 g/d | OR 0.6 | TEn, PA, weight smoking |
| Martìnez, 1996 [ | Ca: 157 | Ca: M = 98 | Ca: 57.7 | n.a. | colorectal adenoma | Ca: 29 | 28.0–86.8 g/d | OR 0.5 | Age, sex, race, BMI, smoking status, family history of CRC, NSAID and aspirin, calcium and fat intake |
| Mathew, 2004 [ | Ca: 239 | Ca: M = | 18–74 (range) | n.a. | colorectal adenoma | n.a. | Median (10th–90th percentiles) 6 (4, 11) of energy from various fibres | OR 0.67 | Age, sex and TEn |
| Mujtaba, 2018 [ | Ca: 789 | Ca: M = 482 | Ca:58.1 ± 9.2 Co:54.5 ± 10.9 | Ca: 21.7 ± 9.4 g/d | colorectal adenoma | Ca: 187 | n.a. | OR 1.25 | Age, sex, family history of CRC, smoking, alcohol, BMI, height, PA, hormone therapy, aspirin use, NSAID calcium, folate, TEn, total fat, SFA, red and processed meat intake |
| Nimptsch, 2014 [ | 17,221 | only F | 34–51 (range) | E: 22.0 ± 5.5 g/d | colorectal adenoma | Ca E: 231 | n.a. | OR 0.77 | TEn |
| Peters, 2003 [ | Ca: 3591 | Ca: M = n.a. | 55–74 (range) | 21.9 g/d | colorectal adenoma | Ca: 637 | 30.6 g/d | OR 0.73 | Age, sex, study center, TEn |
| Peters, 2003 [ | Ca: 2378 | colon adenoma | Ca: 412 | OR 0.70 | |||||
| Peters, 2003 [ | Ca: 659 | rectal adenoma | Ca: 123 | OR 0.93 | |||||
| Platz, 1997 [ | 16,448 | only M | 59.5 ± 9.4 | n.a. | colorectal adenoma | Ca: 120 | 32.3 g/d | RR = 0.88 | Age, endoscopy prior 1986, family history of CRC, BMI, smoking, multivitamin use, PA, aspirin use, alcohol, red meat, folate and methionine |
| Platz, 1997 [ | Ca: 531 | colon adenoma | Ca: 91 | RR: 0.88 | |||||
| Platz, 1997 [ | Ca: 159 | rectal adenoma | Ca: 29 | RR: 1.12 | |||||
| Sandler, 1993 [ | Ca: 105 | only M | Ca:63.5 ± 12.2 | n.a. | colorectal adenoma | Ca: n.a. | ≥18.6 g/d | OR 0.74 | Age, alcohol intake, BMI, and TEn |
| Sandler, 1993 [ | Ca: 131 | only F | Ca:62.2 ± 11.6 | Ca: n.a. | ≥15.6 g/d | OR 0.71 | |||
| Shaw, 2017 [ | Ca: 1098 | Ca: M = 710 | 50–75 (range) | Ca: 10.5–33.59 g/d | colorectal adenoma | Ca:205 | >25.52 g/d | OR 0.77 | Age, sex, BMI, smoking, reason for colonoscopy, family history of polyps, TEn |
| Tantamango, 2011 [ | 2818 | Ca: M = 211 | Ca: 73.4 ± 9.2 | Ca: 11.2 ± 4.3 g/d | colon adenoma | Ca: 93 | 16.9 g/d | OR 0.71 | Age, sex, BMI, education, PA, alcohol and meat intake |
| Witte, 1996 [ | Ca: 488 | Ca: M = 334 | Ca: 61.9 ± 6.7 | Ca: 18.9 ± 9.6 g/d | colorectal adenoma | n.a. | n.a. | OR 0.82 | None |
n.a.: not available; F: Female; M: male; ^ The total sample and number of cases are reported for the cohort study, both the number of Cases (Ca) and Controls (Co) are reported for the case-control study, while the number of Ca and non-cases (no Ca) are reported for the cross-sectional study. BMI: Body Mass Index; Ca/Co: case/control; CRC: Colorectal cancer; IBD: Inflammatory bowel disease; NSAID: Nonsteroidal anti-inflammatory drug; PA: Physical Activity; SAF: Saturated fatty acids; TEn: Total Energy intake.
Figure 2(a) Forest plot and (b) Funnel plot (after trim and fill method) of the meta-analysis comparing dietary fibre intake (lower vs higher intake) and risk of colorectal adenoma (random effect model). In (a) squares represent the effect size values of the individual studies. In (b) white dots represent single studies included. The black dots represent estimated studies after the trim and fill method. The white diamond represents the overall effect size of the included studies. The black diamond represents the estimated overall effect size after the trim and fill method.
Results of the sensitivity and subgroup analyses.
| Analysis | Model | ES | 95% CI |
| Sample Size | I2 |
| Intercept | Tau (t) |
| |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trim and Fill colorectal | Fixed * | 24 | 0.71 | 0.68–0.75 | 0.000 | 157,725 | 62.71 | 0.000 | 0.12 | 0.21 | 0.838 |
| Random ^ | 0.74 | 0.67–0.82 | 0.000 | ||||||||
| Excluding potential overlapping cohort | Fixed | 19 | 0.79 | 0.74–0.85 | 0.000 | 87,629 | 13.00 | 0.295 | −0.89 | −1.93 | 0.070 |
| Random | 0.79 | 0.73–0.86 | 0.000 | ||||||||
| Excluding studies with estimated OR | Fixed | 18 | 0.76 | 0.71–0.82 | 0.000 | 115,311 | 39.33 | 0.045 | −0.84 | −1.41 | 0.179 |
| Random | 0.74 | 0.67–0.83 | 0.000 | ||||||||
| 9y FU | Fixed | 4 | 0.79 | 0.71–0.88 | 0.000 | 56,453 | 0.00 | 0.595 | 0.15 | 0.07 | 0.950 |
| Random | 0.79 | 0.71–0.88 | 0.000 | ||||||||
| Validated FFQ | Fixed | 15 | 0.71 | 0.68–0.75 | 0.000 | 115,192 | 74.88 | 0.000 | 1.16 | 1.14 | 0.276 |
| Random | 0.75 | 0.66–0.86 | 0.000 | ||||||||
| Diagnosis | Fixed | 21 | 0.70 | 0.66–0.73 | 0.000 | 120,530 | 64.52 | 0.000 | 0.09 | 0.14 | 0.891 |
| Random | 0.71 | 0.63–0.80 | 0.000 | ||||||||
| Quality score ≥ 7 | Fixed | 20 | 0.78 | 0.73–0.83 | 0.000 | 125,561 | 38.10 | 0.044 | −0.99 | −1.96 | 0.065 |
| Random | 0.77 | 0.70–0.84 | 0.000 | ||||||||
| Colon adenoma | Fixed | 4 | 0.73 | 0.65–0.83 | 0.000 | 74,714 | 0.00 | 0.774 | 1.20 | 1.20 | 0.352 |
| Random | 0.73 | 0.65–0.83 | 0.000 | ||||||||
| Rectal adenoma | Fixed | 5 | 0.77 | 0.62–0.96 | 0.019 | 69,905 | 30.54 | 0.218 | −0.98 | −0.86 | 0.455 |
| Random | 0.76 | 0.56–1.03 | 0.074 | ||||||||
| Cohort studies (incidence) | Fixed | 10 | 0.67 | 0.63–0.71 | 0.000 | 135,506 | 75.38 | 0.000 | 1.32 | 1.12 | 0.297 |
| Random | 0.72 | 0.61–0.84 | 0.000 | ||||||||
| Case-Control/Cross-sectional (prevalence) | Fixed | 17 | 0.78 | 0.72–0.84 | 0.000 | 55,401 | 25.13 | 0.165 | −0.86 | −189 | 0.079 |
| Random | 0.76 | 0.69–0.85 | 0.000 | ||||||||
| Women | Fixed | 6 | 0.81 | 0.70–0.92 | 0.002 | 35,152 | 0.00 | 0.745 | −0.50 | −1.06 | 0.349 |
| Random | 0.81 | 0.70–0.92 | 0.002 | ||||||||
| Men | Fixed | 6 | 0.69 | 0.58–0.82 | 0.000 | 24,426 | 72.73 | 0.003 | −2.24 | −2.72 | 0.053 |
| Random | 0.46 | 0.27–0.78 | 0.004 |
* Trimmed studies: 0; ^ Trimmed studies: 2.
Figure 3Meta-regression plot for (a) fixed effect model and (b) random effect model.
Figure 4Forest plot of the cumulative analysis by (a) year of publication (from the first to the most recent published study), (b) by sample size (from the smallest to the largest), (c) dietary fibre dose (from the lowest to the highest intake) between dietary fibre intake and risk of colorectal adenoma. Diamonds represent the effect size estimated using the cumulative analysis calculated adding one study at a time.